The need to rapidly scale up production, while maintaining the validated process, in the face of the COVID-19 pandemic left many pharmaceutical manufacturers questioning their increasingly offshore supply chains. But what is the answer when it comes to shoring up supply of raw materials and ensuring production requirements can be met?
Pharmaceutical manufacturing supply chains are complex and, as highlighted by the impact of the Covid-19 pandemic, also fragile. The global Covid-19 pandemic has wreaked havoc with pharmaceutical manufacturing supply chains since it began. At a time when supplies of Active Pharmaceutical Ingredients (APIs), intermediaries and additives needed to be as solid and reliable as ever, it was the very…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
